Corcept Therapeutics Incorporated (NasdaqCM:CORT) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Corcept Therapeutics Incorporated to reach your target.
Based on historical returns, we believe that Corcept Therapeutics Incorporated can grow its free cash at a rate of about 13%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| CORT Price (Corcept Therapeutics Incorporated stock price per share) |
$64.98 | |
|
|
CORT Fair Price (based on intrinsic value) |
$6.78 |
| CORT Safety Price (based on a variable margin of safety) | $4.41 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 141% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 58% lower than other Drug Manufacturers - General stocks | |
| Cash Yield | 0.04% | |
| Free Cash Flow Jitter | 53% | |
In the six months to 2026-11-21, no insider bought shares, and 7 insiders sold in 44 trades, about $38.4 million.
The six months before that had 0 buys and 14 sales.
Open-market buys and sells reported by Corcept Therapeutics Incorporated's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-04 | Guyer William (Chief Development Officer) | Sell | 3,700 | $113.12 |
| 2026-08-03 | Lyon Joseph Douglas (See Remarks) | Sell | 1,540 | $114.16 |
| 2026-08-03 | Maduck Sean (See Remarks) | Sell | 20,305 | $114.70 |
| 2026-07-30 | Mokari Atabak (Chief Financial Officer) | Sell | 400 | $108.46 |
| 2026-07-30 | Mokari Atabak (Chief Financial Officer) | Sell | 15,477 | $114.96 |
| 2026-07-30 | Mokari Atabak (Chief Financial Officer) | Sell | 2,202 | $110.03 |
| 2026-07-30 | Mokari Atabak (Chief Financial Officer) | Sell | 4,700 | $113.18 |
| 2026-07-30 | Mokari Atabak (Chief Financial Officer) | Sell | 600 | $110.95 |
| 2026-07-30 | Mokari Atabak (Chief Financial Officer) | Sell | 8,956 | $106.96 |
| 2026-07-30 | Mokari Atabak (Chief Financial Officer) | Sell | 4,200 | $105.54 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 9,125,717 shares shorted. With 97,814,779 shares available for purchase and an average trading volume over the past 10 trading days of 1,181,290, it would take at least 7.7 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2009 | 1088856 | -18 |
| 2010 | 1088856 | -22.3 |
| 2011 | 1088856 | -27.4 |
| 2012 | 1088856 | -36.1 |
| 2013 | 1088856 | -37.1 |
| 2014 | 1088856 | -27.5 |
| 2015 | 1088856 | 3 |
| 2016 | 1088856 | 18.3 |
| 2017 | 1088856 | 60.7 |
| 2018 | 1088856 | 115 |
| 2019 | 1088856 | 136 |
| 2020 | 1088856 | 151 |
| 2021 | 1088856 | 167 |
| 2022 | 1088856 | 120 |
| 2023 | 1088856 | 126 |
| 2024 | 1088856 | 197 |
| 2025 | 1088856 | 141 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 10 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $1,238 million against net income of $974 million, or 1.27 times. Net income was negative in 7 of the 17 years, and those years are left out of the ratio.
In 2025, capital expenditures were $0.2 million, 0.1% of operating cash flow of $142 million, which leaves an estimated $142 million after capex. Across the 11 years with reported capex, it averaged 0.5% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2009 | -20.2 | -18 | not reported | n/a |
| 2010 | -26 | -22.3 | not reported | n/a |
| 2011 | -32.4 | -27.4 | 0 | n/a |
| 2012 | -38 | -36 | 0.2 | n/a |
| 2013 | -46 | -37.1 | 0.1 | n/a |
| 2014 | -31.4 | -27.4 | 0.2 | n/a |
| 2015 | -6.4 | 3.1 | 0 | n/a |
| 2016 | 8.1 | 18.4 | 0.2 | 2.26 |
| 2017 | 129 | 60.9 | 0.4 | 0.47 |
| 2018 | 75.4 | 116 | 0.3 | 1.53 |
| 2019 | 94.2 | 136 | 1.1 | 1.45 |
| 2020 | 106 | 152 | 1.2 | 1.43 |
| 2021 | 113 | 168 | 0.5 | 1.49 |
| 2022 | 101 | 120 | 0.4 | 1.19 |
| 2023 | 106 | 127 | 0.1 | 1.19 |
| 2024 | 141 | 198 | 2.2 | 1.40 |
| 2025 | 99.7 | 142 | 0.2 | 1.42 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 5 fiscal years from 2018 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $741 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In 5 of the 5 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $253 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2025, cash spent repurchasing shares was $173 million, 122.4% of estimated free cash flow of $141 million. That was more than the estimated free cash flow of the year.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2018 | 115 | n/a | 23.7 | 23.7 | 20.5% |
| 2019 | 136 | n/a | 31 | 31 | 22.8% |
| 2020 | 151 | n/a | 9.9 | 9.9 | 6.6% |
| 2024 | 197 | n/a | 15.7 | 15.7 | 7.9% |
| 2025 | 141 | n/a | 173 | 173 | 122.4% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $0 million in 2009 and $761 million in 2025, a compound annual growth rate of 88.9% over 16 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.
Revenue rose 12.8% from 2024 to 2025.
Our estimated free cash flow was $141 million in 2025, 18.6% of revenue. In 2009 the estimated margin was negative 61958.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 0 | -18 | -61958.6% |
| 2016 | 81.3 | 18.3 | 22.5% |
| 2017 | 159 | 60.7 | 38.2% |
| 2018 | 251 | 115 | 45.9% |
| 2019 | 306 | 136 | 44.3% |
| 2020 | 354 | 151 | 42.8% |
| 2021 | 366 | 167 | 45.7% |
| 2022 | 402 | 120 | 29.8% |
| 2023 | 482 | 126 | 26.1% |
| 2024 | 675 | 197 | 29.2% |
| 2025 | 761 | 141 | 18.6% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $120 million against total liabilities of $189 million, or 63.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 22.6% of total assets in 2025, compared with 15.4% in 2010, an increase of 7.2 percentage points.
Stockholders equity was $648 million in 2025, compared with $21.2 million in 2010, a rise of 2949.4%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 25.7% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 25.1 | 24.6 | 3.9 | 21.2 |
| 2011 | 39.8 | 39.6 | 5 | 34.8 |
| 2012 | 99.2 | 93 | 37.4 | 61.8 |
| 2013 | 63.1 | 54.9 | 42.1 | 21 |
| 2014 | 34.6 | 24.2 | 38 | -3.4 |
| 2015 | 51.9 | 40.4 | 33.4 | 18.5 |
| 2016 | 68.8 | 51.5 | 27.4 | 41.4 |
| 2017 | 221 | 31.1 | 29.6 | 191 |
| 2018 | 312 | 41.6 | 35.8 | 276 |
| 2019 | 412 | 31.3 | 41.1 | 371 |
| 2020 | 572 | 76.2 | 48.4 | 523 |
| 2021 | 424 | 77.6 | 48 | 376 |
| 2022 | 583 | 66.3 | 81.6 | 502 |
| 2023 | 622 | 136 | 115 | 507 |
| 2024 | 841 | 128 | 161 | 680 |
| 2025 | 837 | 120 | 189 | 648 |
How to read this: discounted cash flow, intrinsic value.
At today's price of $64.98, the price is above what our model can produce for average free cash flow growth between -30 and 60 percent a year, so no implied growth rate is shown. Our model assumes 13.3 percent a year for this stock. This is not a forecast of growth or a price target.
The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.
The model starts from the company's average free cash flow of $3.1 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.
The baseline is the company's average free cash flow, and cyclical companies can mislead it.
| Case | Price per share | Average annual free cash flow growth |
|---|---|---|
| 20 percent below the current price | $51.98 | above range |
| Current price | $64.98 | above range |
| 20 percent above the current price | $77.98 | above range |
| Our model (stored fair price) | $6.78 | 13.3% |
Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.
Positive free cash flow appears in 11 of the 17 fiscal years we hold for Corcept Therapeutics Incorporated from its current SEC filer.
Our fair value estimate for Corcept Therapeutics Incorporated is $6.78, below its current price of $64.98.
Year-to-year variability in free cash flow is volatile, measured at 53%.
No dividend yield is recorded for Corcept Therapeutics Incorporated in our data.
These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 141% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 58% below the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Corcept Therapeutics Incorporated, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Corcept Therapeutics Incorporated (CORT) | 7,112 | 48.9 | - | 0.0% | 858% above |
| Alkermes plc (ALKS) | 7,552 | - | - | 1.5% | 315% above |
| Prestige Consumer Healthcare (PBH) | 2,352 | 15.3 | - | 7.8% | 50% below |
| Perrigo Company plc (PRGO) | 2,213 | - | 7.2% | 72.9% | 91% below |
| ANI Pharmaceuticals (ANIP) | 1,558 | 13.9 | - | - | 188% above |
| Elanco Animal Health Incorporated (ELAN) | 12,866 | - | - | - | 96% above |
| Phibro Animal Health Corporation (PAHC) | 1,352 | 13.9 | 1.4% | - | 82% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1088856.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: CORT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Corcept Therapeutics Incorporated have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to CORT: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
How Does Portfolio Churning Affect Your Returns?
Insider Buying as a Conviction Signal
What is Market Capitalization?
What is Cash Return on Invested Capital?